Showing 1 - 2 of 2 results
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Radotinib (Supect) was developed and approved in Korea as a second-line Chronic Myeloid Leukemia treatment. The drug supresses cancer cells proliferation by inhibitiing BCR-ABL1 kinase which is a driver of Philadelphia chromosome-positive (Ph+) leuke...
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Radotinib (Supect) was developed and approved in Korea as a second-line Chronic Myeloid Leukemia treatment. The drug supresses cancer cells proliferation by inhibitiing BCR-ABL1 kinase which is a driver of Philadelphia chromosome-positive (Ph+) leuke...